Monitor for actual Form 4 filings confirming the sale. A sale of this magnitude by a director could signal a lack of near-term confidence or a planned diversification. The stock may face selling pressure as the market prices in the potential overhang.
Price Chart
Executive Summary
Director Edward M. Kaye, MD, filed a Form 144 on October 21, 2026, indicating intent to sell shares of Stoke Therapeutics. The filing covers the cashless exercise of options and subsequent sale of approximately 1.6 million shares (1,496,042 shares across multiple option tranches), with an estimated aggregate market value of approximately $38.4 million based on the filing date. This is a large-scale insider sale by a director, signaling potential near-term selling pressure.
Key Facts
- Director Edward M. Kaye, MD, filed a Form 144 on October 21, 2026.
- The filing covers the cashless exercise of options and subsequent sale of 1,496,042 shares of common stock.
- Estimated aggregate market value of the proposed sale is approximately $38.4 million.
- The sale is planned to commence on October 21, 2026.
- The filing notes the shares were acquired through the exercise of options under a registered plan.
Financial Impact
Proposed sale of ~1.5 million shares valued at ~$38.4 million, representing a significant portion of the director's holdings and a notable percentage of the company's market cap.
Risk Factors
- Large insider sale may signal negative sentiment or lack of confidence from a key director.
- Potential overhang of ~1.5 million shares could pressure the stock price in the near term.
- The sale is planned to begin immediately, increasing the risk of near-term price weakness.
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-010349 |
| Document: 0001950047-26-010349-index.html | 0001950047-26-010349 |
| Document: 0001950047-26-010349.txt | 0001950047-26-010349 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 6d ago | 144 | $25.70 | awaiting T+20 | awaiting T+20 | $26.35 (−2.55%) |
Sep 30, 2026 27d ago | SC 13G | $26.01 | awaiting T+20 | awaiting T+20 | $26.35 (+1.33%) |
Sep 25, 2026 4w ago | 8-K | $25.50 $25.46 | ▼ −0.16% | ▼ −0.13% | $26.35 (+3.35%) |
Aug 18, 2026 10w ago | Insider Cluster | $33.03 $28.93 | ▼ −12.41% | ▼ −10.46% | $26.35 (−20.21%) |
Aug 3, 2026 12w ago | 8-K | $31.67 $30.89 | ▲ +2.46% | ▲ +1.22% | $26.35 (+16.78%) |
Aug 3, 2026 12w ago | 424B5 | $31.67 $30.89 | ▲ +2.46% | ▲ +1.22% | $26.35 (+16.78%) |
Jun 30, 2026 17w ago | 8-K | $32.72 $29.31 | ▼ −10.42% | ▼ −9.39% | $26.35 (−19.45%) |
May 7, 2026 24w ago | 8-K | $32.89 $30.01 | ▼ −8.76% | ▼ −8.78% | $26.35 (−19.87%) |
Apr 22, 2026 26w ago | DEFA14A | $34.93 $30.30 | ▼ −13.27% | ▼ −17.90% | $26.35 (−24.55%) |
Apr 7, 2026 29w ago | 8-K | $34.87 $32.96 | ▼ −5.48% | ▼ −14.02% | $26.35 (−24.42%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers